NRG Therapeutics has closed an oversubscribed £50 million (about $67 million) Series B financing, the company said that the round was led by SV Health Investors’ Dementia Discovery Fund, and included British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, along with existing investors Omega Funds and Brandon Capital.
The company said that the funding will support clinical proof-of-concept studies in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and enable the generation of Phase 1b clinical data in Parkinson’s patients. NRG Therapeutics’ lead candidate, NRG5051, is a first-in-class, orally available inhibitor of the mitochondrial permeability transition pore (mPTP), which the company claims has demonstrated strong neuroprotective effects and reduced neuroinflammation in pre-clinical models of both diseases.
The company said that NRG5051 has completed IND-enabling studies and is on track to enter first-in-human clinical trials in early 2026. The company said that this financing provides the runway to advance its pipeline of small-molecule therapeutics targeting mitochondrial dysfunction through clinical milestones.
The company said that as part of the Series B, representatives from SV Health Investors, British Business Bank, M Ventures, and Novartis Venture Fund will join its board of directors, and that Parkinson’s UK has appointed a special advisor on Parkinson’s research.
